Denibulin Hydrochloride
Denibulin Hydrochloride had been in phase I clinical trials for the treatment of solid tumours. However, no recent development has been reported.
This compound was originally discovered by Angiogene Pharmaceuticals, then licensed to MediciNova in July 2002.
General Information
Update Date：2016-04-07
- Drug Name：
- Denibulin Hydrochloride
- Research Code：
- ANG-615； MN-029
- Trade Name：
- MOA：
- Tubulin polymerization inhibitor; Vascular disrupting agent
- Indication：
- Solid tumours
- Status：
- Phase Ⅰ (Pending)
- Company：
- Angiogene (Originator) , MediciNova
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-12-14
|
Molecular Weight | 421.90 | ||||||||||||
| Formula | C18H19N5O3S • HCl | |||||||||||||
| CAS No. |
284019-34-7 (Denibulin); 779356-64-8 (Denibulin hydrochloride); |
|||||||||||||
| Chemical Name | Carbamic acid, N-[6-[[4-[[(2S)-2-amino-1-oxopropyl]amino]phenyl]thio]-1H-benzimidazol-2-yl]-, methyl ester, hydrochloride (1:1) | |||||||||||||
| Denibulin （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||